Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01114672 · ClinicalTrials.gov registry record · Phase 4
A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients
A Phase 4 study of Pruritis, sponsored by Winthrop University Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT01114672: Completed Phase 4 study of Pruritis, sponsored by Winthrop University Hospital.
NCT01114672 is a Phase 4 study of Pruritis that has completed, run by Winthrop University Hospital. The registered enrollment target is 50 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01114672, a Phase 4 study of Pruritis, has completed, sponsored by Winthrop University Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
Pruritis (itching) is common in many people with chronic renal failure on hemodialysis. There may be many different reasons for the pruritis. Efforts to treat the problem have not been very effective. Vitamin D levels have been found to be low in many hemodialysis patients. Since vitamin D plays an important role in the skin and is effective in treatment of certain skin conditions that involve pruritis, it may have a role in treatment of pruritis in hemodialysis patients. The objective of the investigators study is to determine the effect of supplementation with oral vitamin D2 (ergocalciferol) on pruritis in hemodialysis patients.
Primary Outcome
Randomized patients will fill out a survey with questions about the degree and location of their pruritis at baseline and end of study. The total score ranged from 0-21 with 21 being the most severe and zero being the absence of any of the measures of pruritis. Last observation was carried forward to end of study. A decrease in the Severity of Pruritis score over time indicated an improvement in the severity of pruritis.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG 50,000 Units Ergocalciferol
Study Locations (2)
New York
- Winthop Univ Hospital Outpatient Dialysis at Bethpage - Bethpage
- Winthrop Univ Hospital Outpatient Dialysis - Mineola
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-02 |
| Phase | Phase 4 |
What the finished NCT01114672 record still lists
NCT01114672 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Pruritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01114672 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01114672 about?
NCT01114672 is a clinical study titled "A Study of Oral Ergocalciferol to Treat Pruritis in Hemodialysis Patients". Pruritis (itching) is common in many people with chronic renal failure on hemodialysis. There may be many different reasons for the pruritis. Efforts to treat the problem have not been very effective. Vitamin D levels have been found to be low in many hemodialysis patients. Since vitamin D plays an...
What is the current status of trial NCT01114672?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2010-07. Estimated completion is 2012-02.
What conditions does trial NCT01114672 study?
This clinical trial studies the following conditions: Pruritis.
What interventions are being tested in trial NCT01114672?
The interventions under investigation include: Placebo (DRUG), 50,000 Units Ergocalciferol (DRUG).
Who is sponsoring clinical trial NCT01114672?
This trial is sponsored by Winthrop University Hospital, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01114672 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pruritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01114672's enrollment target sits among peer trials
50 1255th of 2000 higher than 678 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia